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Association between cytokine 
response, the LRINEC score 
and outcome in patients with 
necrotising soft tissue infection: a 
multicentre, prospective study
Marco Bo Hansen1,2, Lars Simon Rasmussen1, Mattias Svensson3, Bhavya Chakrakodi3, 
Trond Bruun4, Martin Bruun Madsen5, Anders Perner5, Peter Garred6, Ole Hyldegaard1,2,*, 
Anna Norrby-Teglund3,* &  INFECT study group#
Early assessment of necrotising soft tissue infection (NSTI) is challenging. Analysis of inflammatory 
markers could provide important information about disease severity and guide decision making. For 
this purpose, we investigated the association between cytokine levels and the Laboratory Risk Indicator 
for Necrotising Fasciitis (LRINEC)-score, disease severity and mortality in NSTI patients. In 159 patients, 
plasma was analysed for IL-1β, IL-6, IL-10 and TNF-α upon admission. The severity of NSTI was assessed 
by SAPS, SOFA score, septic shock, microbial aetiology, renal replacement therapy and amputation. 
We found no significant difference in cytokine levels according to a LRINEC- score above or below 6 
(IL-1β: 3.0 vs. 1.3; IL-6: 607 vs. 289; IL-10: 38.4 vs. 38.8; TNF-α: 15.1 vs. 7.8 pg/mL, P > 0.05). Patients 
with β-haemolytic streptococcal infection had higher level of particularly IL-6. There was no difference 
in mortality between patients with a LRINEC-score above or below 6. In the adjusted analysis assessing 
30-day mortality, the association was strongest for IL-1β (OR 3.86 [95% CI, 1.43-10.40], P = 0.008) and 
IL-10 (4.80 [1.67-13.78], P = 0.004). In conclusion, we found no significant association between the 
LRINEC-score and cytokine levels on admission. IL-6 was consistently associated with disease severity, 
whereas IL-1β had the strongest association with 30-day mortality.
Necrotising soft tissue infection (NSTI) is a serious disease that causes necrotic lesions in any layer within the 
soft tissue compartments. The incidence of NSTI has increased over the past decades and the mortality and 
amputation rate remain high despite increased focus on these patients1,2. However, limited data exist on the 
disease burden in Scandinavia. A 13-year-old active surveillance, performed in Denmark, showed that invasive 
streptococcal infections had an incidence of 2.6 cases per 100,000 person-years and that NSTI accounted for 6%3. 
A retrospective study from western Norway reported an incidence of streptococcal NSTI of 1.4 cases per 100,000 
person-years4. Even though NSTI is uncommon, many physicians will encounter at least one case during their 
working life5.
The pathogenesis of NSTI has not yet been fully elucidated, but toxin-induced inflammatory responses are 
believed to be involved in both tissue pathology and systemic toxicity6,7. Interleukin-1β (IL-1β ), IL-6, IL-10 and 
tumor necrosis factor-α (TNF-α ) are some of the classical sepsis-associated cytokines. We know that plasma lev-
els of the pro-inflammatory cytokines (e.g. IL-1β , IL-6, TNF-α ) and anti-inflammatory cytokines (e.g. IL-10) are 
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elevated in patients with sepsis not surviving on Day 28 compared with the levels in survivors8. There are only few 
prospective studies aimed at characterizing the systemic cytokine responses in patients with NSTI and they are 
based on small samples, investigating fewer than 20 patients9,10. Further insight into the cytokine response profile 
in NSTI of varying severity and aetiology is needed to forward our understanding of the pathophysiology and to 
identify potential targets for improved diagnostics and interventions.
A key challenge is the presentation of the disease as it is often indistinguishable from non-necrotising infec-
tions11. Accordingly, the Laboratory Risk Indicator for Necrotising Fasciitis (LRINEC) score was developed as a 
diagnostic scoring system to detect early cases of NSTI12; a cut-off of a LRINEC score ≥ 6 was observed to have 
the highest predictive values12. The score has also been associated with clinical outcomes, including amputation 
and death13,14. However, other studies have been unable to find clear associations between the LRINEC score 
and clinically important outcomes15–17. Identifying biomarkers that reflect the inflammatory state in patients 
with NSTI would be desirable because such biomarkers might prove usefulness for prognostication and guide 
treatment. C-reactive protein (CRP) is one of the 6 variables included in the LRINEC score and has been found 
elevated in non-surviving patients with NSTI14. IL-6 induces CRP production during acute inflammation and 
might therefore be a relevant biomarker to elaborate on in this patient group.
Accordingly, we aimed to investigate the association between plasma levels of inflammatory cytokines and 
disease severity in patients with NSTI. We focused primarily on the association between baseline IL-6 level and 
the LRINEC score. We hypothesized that high IL-6 level upon hospital admission was associated with a high 
LRINEC score. Secondarily, we focused on the association between IL-1β , IL-6, IL-10 and TNF-α level and the 
simplified acute physiology score II (SAPS II) and Sepsis-related organ failure assessment (SOFA) score, septic 
shock, β -haemolytic streptococcal infection, renal replacement therapy (RRT), amputation and 30-day mortality.
Results
We enrolled 270 patients with NSTI during the 33 months of inclusion between February 2013 and November 
2015 of whom 68 had missing data for the LRINEC score (Fig. 1). Of the remaining 202 patients with a LRINEC 
score, we randomly selected 159 patients according to the sample size calculation and measured the plasma 
cytokine levels. One foreign patient was lost to follow-up as he left the country on Day 7 and was excluded from 
the survival analyses. In 31 patients, SAPS II could not be calculated due to missing values.
Table 1 shows baseline characteristics of the 159 included patients, which appeared to be similar between the 
groups with the exception of the variables included in the LRINEC score (CRP, sodium, creatinine) and organ dis-
eases affecting these variables (chronic kidney disease). In 61% of the cases, the baseline samples of the cytokines 
were obtained after the first operation with a median of 3.5 hours. The rest of the samples were obtained just prior 
to surgery. There was no difference in baseline cytokine level in samples obtained prior to and after operation 
according to IL-1β (3.1 (IQR, 0, 7–9.1) vs. 2.1 (0.6–7.1) pg/mL, P = 0.54), IL-6 (733 (IQR, 116–3,090) vs. 381 
(172–2,395) pg/mL, P = 0.64), IL-10 (50.3 (IQR, 11.1–198.3) vs. 36.5 (9.9–80.2) pg/mL, P = 0.13) and TNF-α 
(15.2 (IQR, 5.0–59.7) vs. 13.1 (3.6–37.4) pg/mL, P = 0.32).
LRINEC score. A LRINEC score ≥ 6 was seen in 116 (73%) patients. Those with a LRINEC score ≥ 6 had 
a mean IL-6 level of 8,006 pg/mL, whereas those with a score < 6 had a mean IL-6 level of 10,729 pg/mL (mean 
difference 2,723 pg/mL, 95% CI [−6,947 to 12,393], P = 0.58). Likewise, no significant difference was found in 
any of the cytokine levels between the two groups using a Mann-Whitney U-test and median values (Fig. 2). In 
line with this, we found no significant correlation between the baseline levels of the cytokines and the LRINEC 
score (Table 2). In contrast, all cytokines showed a significant correlation with the severity scores of SAPS II 
and SOFA, as well as with CRP, creatinine and lactate with IL−6 demonstrating the highest correlation with 
Figure 1. Flow chart of patient inclusion. Only patients with a LRINEC score had plasma analysed according 
to the primary analysis. LRINEC, Laboratory Risk Indicator for Necrotising Fasciitis; NSTI, Necrotising soft 
tissue infection.
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Study cohort (n = 159) LRINEC <6 (n = 43) LRINEC ≥6 (n = 116) P-value
Age, years 61 (53–69) 60 (47–68) 61 (54–69) 0.30
Sex, male 95 (60) 27 (63) 68 (59) 0.63
Chronic disease
Diabetes 34 (21) 5 (12) 29 (25) 0.07
Liver cirrhosis 7 (4) 2 (5) 5 (4) 0.93
Chronic kidney disease 16 (10) 0 (0) 16 (14) 0.01
Cardiovascular disease 68 (43) 16 (37) 52 (45) 0.39
COPD 16 (10) 6 (14) 10 (9) 0.38
Peripheral vascular disease 21 (13) 1 (2) 20 (17) 0.01
Immune deficiency (AIDS) 1 (1) 1 (2) 0 (0) 0.30
Malignancy 23 (15) 4 (9) 19 (16) 0.26
Rheumatoid disease 11 (7) 3 (7) 8 (7) 0.99
Steroid treatment 19 (12) 8 (19) 11 (10) 0.12
Symptoms
Severe pain requiring opioid 52 (33) 13 (30) 39 (34) 0.92
Palpable gas (crepitus) 24 (15) 4 (9) 20 (17) 0.45
Gas visualized with CT 40 (25) 9 (21) 31 (27) 0.38
Cytokines, pg/mL
IL-1β 2.3 (0.7–7.3) 1.3 (0.4–5.4) 3.0 (0.8–7.9) 0.07
IL-6 539 (156–2,484) 289 (88–3,050) 607 (181–2,473) 0.23
IL-10 38.8 (10.0–115.4) 38.8 (6.7–97.9) 38.4 (11.7–129.7) 0.45
TNF-α 15.1 (4.3–49.8) 7.8 (3.1–68.2) 15.1 (5.3–45.8) 0.26
Time from diagnosis to baseline blood 
sample (hours) 3.5 (1.5–8.75) 3.25 (1.0–11.75) 3.75 (1.75–8.75) 0.49
Body part affected on admission
Head/neck 12 (7) 4 (9) 8 (7) 0.54
Thorax 6 (4) 0 (0) 6 (5) 0.19
Abdomen 3 (2) 1 (2) 2 (2) 0.21
Extremities 65 (41) 22 (51) 43 (37) 0.11
Genital/perineum 33 (21) 9 (21) 24 (21) 0.28
Multiple body regions 40 (25) 7 (17) 33 (28) 0.12
Microorganism in blood and/or tissue
β -haemolytic Streptococcus 49 (31) 12 (28) 37 (32) 0.63
Staphylococcus aureus 6 (4) 2 (5) 4 (3) 0.66
Gram-negative bacteria 13 (8) 4 (9) 9 (8) 0.75
Monomicrobial, other 23 (14) 7 (16) 16 (14) 0.69
Polymicrobial 41 (26) 10 (23) 31 (27) 0.66
Negative findings 27 (17) 8 (19) 19 (16) 0.74
Biochemistry
Leukocyte count (highest), 10⁹/L 15.9 (9.4–23.8) 15.9 (7.6–21.5) 15.9 (9.7–24.3) 0.71
C-reactive protein (highest), mg/L 201 (126–296) 96 (54–197) 226 (159–306) < 0.0001
Potassium (highest), mmol/L 4.3 (3.9–4.8) 4.2 (4.0–4.7) 4.4 (3.9–4.8) 0.83
Sodium (lowest), mmol/L 135 (131–138) 137 (134–139) 134 (131–137) 0.005
Creatinine (highest), μ mol/L 121 (77–209) 91 (64–129) 145 (80–233) 0.001
pH (lowest) 7.31 (7.22–7.37) 7.36 (7.23–7.40) 7.30 (7.2–7.4) 0.05
Lactate (highest), mmol/L 2.3 (1.3–4.2) 1.9 (1.1–4.1) 2.4 (1.4–4.4) 0.26
Outcomes and ICU scores
SAPS IIa 46 (35–55) 47 (31–58) 45 (36–52) 0.92
SOFA scoreb (Day 1) 8 (5–10) 6 (3–10) 8 (6–10) 0.17
Septic shockc (Day 1) 116 (73) 28 (65) 88 (76) 0.18
Ventilation within 7 d 142 (89) 34 (79) 108 (93) 0.019
RRT within 7 d 40 (25) 12 (28) 28 (24) 0.63
Amputation of extremity within 7 d 29 (18) 8 (19) 21 (18) 0.94
30-day mortality, % (95% CI) 25 (16, 11–22) 10 (23) 15 (13) 0.24
90-day mortality, % (95% CI) 34 (21, 16–28) 12 (28) 22 (19) 0.41
Table 1.  Baseline characteristics of patients with necrotising soft tissue infection for the entire study 
cohort and according to the LRINEC score. COPD, chronic obstructive pulmonary disease; CT, computed 
tomography; SAPS II, simplified acute physiology score II; SOFA, sequential organ failure assessment; LRINEC, 
laboratory risk indicator for necrotising fasciitis; ICU, intensive care unit; RRT, renal replacement therapy. 
Values denote median (25–75 percentiles) or number (%). Comparisons between LRINEC < 6 and ≥ 6 were 
performed with Mann-Whitney U or X2-test. aPatients with missing value: n = 31. bPatients with missing value: 
n = 14; the SOFA score was modified as the Glasgow Coma Scale was not assessed. cSeptic shock defined as the 
use of any inotropica or vasopressor.
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these variables. The cytokine levels were significantly greater in the infected patients than in the control patients 
(Table 3). Moreover, patients with NSTI and septic shock at baseline had significantly higher levels of IL-1β , IL-6, 
IL-10 and TNF-α level than in patients with NSTI without shock. Patients with a LRINEC score ≥ 6 did not have 
a significantly higher presence of septic shock compared with patients with a LRINEC score < 6 nor did they have 
a higher rate of death at Day 30 (Table 1).
Microbiology. Infection with β -haemolytic Streptococcus was the most common monomicrobial finding in 
the patients (n = 49, Table 1). Of these, group A was present in 39 patients, group B in one patient, group C in 
4 patients and group G in 5 patients. The cytokine levels according to microbiology are illustrated in Fig. 3. 
Compared with patients with other bacterial infections, those with β -haemolytic streptococcal infection had 
higher levels of IL-6, IL-10 and TNF-α but not a higher IL-1β level (Table 3). There was no significant difference 
between patients infected with β -haemolytic Streptococcus or non-Streptococcus according to amputation (14% 
[95% CI, 7–27] vs. 20% [95% CI, 14–29], P = 0.39) and 30-day mortality (12% [95% CI, 5–25] vs. 17% [95% CI, 
11–26], P = 0.41). However, patients infected with β -haemolytic Streptococcus were more likely to have septic 
shock than were non-Streptococcus infected patients (84% [95% CI, 71–92] vs. 68% [95% CI, 59–76], P = 0.04). 
Moreover, patients with the presence of bacteraemia, defined as having a positive blood culture, had higher levels 
Figure 2. Levels of plasma cytokines on admission according to the LRINEC score in patients with 
necrotising soft tissue infection. LRINEC, Laboratory Risk Indicator for Necrotising Fasciitis. Filled circles 
and squares indicate patients with septic shock. Median with interquartile range is illustrated. Comparisons 
were performed using the Mann-Whitney U test.
IL-1β IL-6 IL-10 TNF-α
Rho P Rho P Rho P Rho P
LRINEC 0.12 0.14 0.10 0.24 0.09 0.29 0.05 0.55
SAPS II 0.30 0.001 0.41 < 0.0001 0.34 < 0.0001 0.33 < 0.0001
SOFA score 0.34 < 0.0001 0.51 < 0.0001 0.42 < 0.0001 0.44 < 0.0001
Leucocyte count − 0.02 0.81 − 0.08 0.31 − 0.05 0.57 − 0.13 0.11
CRP 0.18 0.03 0.17 0.05 0.04 0.67 0.09 0.29
Creatinine 0.34 < 0.0001 0.47 < 0.0001 0.37 < 0.0001 0.38 < 0.0001
Lactate 0.58 < 0.0001 0.70 < 0.0001 0.58 < 0.0001 0.64 < 0.0001
Table 2.  Spearman rank correlation between variables and baseline biomarker levels in patients with 
necrotising soft tissue infection. LRINEC, laboratory risk indicator for necrotising fasciitis; SAPS II, simplified 
acute physiology score II; SOFA, sequential organ failure assessment; CRP, c-reactive protein.
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of IL-6 (1296 vs. 380 pg/mL, P = 0.01) and TNF-α (24.78 vs. 11.97 pg/mL, P = 0.02) than those with negative 
blood cultures. No difference was found according to IL-1β (2.47 vs. 1.88 pg/mL, P = 0.25) or IL-10 (44.31 vs. 
37.99 pg/mL, P = 0.49).
Clinical outcomes. The 30-day mortality was higher if baseline cytokine levels were above the median 
(Table 4). The odds ratio was larger for IL-10, but IL-1β proved to be more consistent in predicting 30-day mortal-
ity when adjustments for baseline risk factors were performed. The diagnostic value for the prediction of 30-day 
mortality was the highest for IL-1β and IL-10 (Table 5). Patients who subsequently received RRT had higher 
median levels of IL-1β , IL-6, IL-10 and TNF-α (Table 3) than did those not receiving RRT. Patients who under-
went amputation did not have a higher median IL-1β level but had higher median levels of IL-6, IL-10 and TNF-α 
compared with those not amputated (Table 3).
The cytokine response to surgery. The 43 non-infected control patients (61% men) had a median age of 
63 years (IQR, 45–71), CRP of 3 mg/L (IQR, 1–5) and a leucocyte count of 7.1 109/L (IQR, 6.3–9.8). They expe-
rienced a significant increase in IL-6 and IL-10 levels after surgery compared with samples taken before surgery, 
whereas the levels of IL-1β and TNF-α were not significantly altered by surgery (Fig. 4).
Discussion
In this prospective study of patients with NSTI, we found that baseline cytokine levels were not significantly 
different in patients with a LRINEC score ≥ 6 compared with a score < 6. Notably, the cytokine levels were asso-
ciated with the severity of infections as evident by significantly elevated levels in patients with septic shock and 
positive correlations with the severity scores (SAPS II and SOFA). Moreover, there was an association between 
high cytokine levels and subsequent use of RRT, amputation and 30-day mortality.
NSTI is a difficult diagnosis for the clinicians to make. This is evident in our prospective study of NSTI 
patients with only 15% having crepitus, 25% having gas visualized with CT and 33% having severe pain and 
requiring opioid (Table 1). Even though the LRINEC score was designed to discriminate between NSTI and 
non-NSTI, it is primarily believed to be useful in the context of strongly suspected NSTI5,18. Our data suggest that 
the score should be used with caution as only 73% of patients with NSTI had a LRINEC score of ≥ 6. However, 
this needs to be investigated further in a larger patient cohort. Additionally, among the baseline data presented 
in Table 1, variables included in the LRINEC score, i.e. sodium, creatinine and CRP, were significantly higher in 
patients with a score of ≥ 6 as a consequence of the stratification but this was not the case with the severity scores 
or infection outcome measures. We did not detect a significant difference in baseline IL-6 level in patients with a 
score < 6 vs. ≥ 6, but the rather wide 95% CI indicates a risk of overlooking a clinically relevant difference in IL-6 
level as defined in our sample size calculation. This is related to the large variability in IL-6 level and in line with 
other studies of severe infections19,20.
CRP is included in the LRINEC score and often used to monitor disease progression in patients with NSTI. 
CRP is released from hepatic cells after stimulation of IL-6 amongst others21. Because we found a significant 
difference in CRP levels between the groups of high vs. low LRINEC score, a similar trend for LRINEC and IL-6 
would be expected. The lack of an association could be related to the time course of the inflammatory state as 
IL-6 levels peak within hours of infection, whereas CRP reaches its peak after around 48 hours22. However, this 
is unlikely as IL-6 was significantly higher in patients with septic shock, β -haemolytic streptococcal infection 
and in patients undergoing amputation or given RRT. Moreover, the median time from diagnosis of NSTI until 
blood sampling was 3.5 hours with no significant difference between patients with high and low LRINEC scores 
(Table 1). It seems more plausible that the LRINEC score does not reflect the inflammatory state in the patients. 
This is an important finding because it might explain why several studies have failed to prove an association 
between a high LRINEC score and the presence of NSTI and disease severity15–17,23,24. This study was not designed 
to evaluate the diagnostic value of the LRINEC score. Instead we focused on the potential value of the score as a 
measure of disease severity and the ability to predict adverse outcomes of NSTI. The data are important as they 
dispute earlier claims of the LRINEC score being able to predict disease severity13,14. A natural next step would be 
IL-1β P IL-6 P IL-10 P TNF-α P
Septic shock 3.1 (1.0–8.3)
0.0008
982 (233–3475)
< 0.0001
50.4 (17.8–183.7)
< 0.0001
19.5 (6.0–55.5)
< 0.0001
No septic shock 0.9 (0.4–5.7) 156 (69–541) 14.7 (4.8–42.2) 5.3 (3.1–15.2)
β -haemolytic 
strep. 4.1 (0.9–12.0) 0.052
1628 (298–15611)
< 0.0001
66.2 (16.1–218.5)
0.03
26.1 (7.6–140.1)
0.007
Other infectionsa 1.7 (0.6–6.9) 313 (117–1778) 36.5 (8.4–93.2) 11.5 (3.5–30.0)
RRTb 4.9 (1.3–11.9)
0.02
2649 (284–12942)
< 0.0001
71.6 (11.6–243.3)
0.03
48.4 (9.1–174.9)
< 0.001
No RRT 1.7 (0.6–5.7) 373 (129–1618) 35.3 (9.4–87.8) 11.2 (3.7–28.0)
Amputationb 3.0 (1.3–11.5)
0.12
2019 (364–5799)
0.02
79.2 (39.0–330.9)
0.0008
33.8 (5.2–107.6)
0.04
No amputation 1.8 (0.6–7.2) 420 (140–1952) 33.7 (8.8–95.6) 12.5 (4.3–35.1)
NSTI 2.3 (0.7–7.3)
< 0.0001
539 (156–2484)
< 0.0001
38.8 (10.0–115.4)
< 0.0001
15.2 (4.3–49.8)
< 0.0001
Surgical controls 0.0 (0.0–0.7) 0.0 (0.0–2.4) 1.2 (0.2–8.3) 0.8 (0.0–17.8)
Table 3.  Differences in median baseline cytokine levels and disease severity in patients with necrotising 
soft tissue infection. Strep., streptococcus infection; RRT, renal replacement therapy; NSTI, necrotising soft 
tissue infection. aAll other types of microorganisms than monomicrobial β -haemolytic strep. infection. bWithin 
the first 7 days of admission.
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Figure 3. Levels of plasma cytokines on admission according to microbial aetiology in patients with 
necrotising soft tissue infection. Median with interquartile range is illustrated. Comparisons were performed 
using the Mann-Whitney U test. NS, non-significant; *p < 0.05; **p < 0.01; ***p < 0.0001. Monomicrobial 
infection, other includes Staphylococcus aureus, Enterococcus faecium, Escherichia coli, Clostridium septicum, 
Clostridium perfringens, Corynebacterium amycolatum or gram-negative rods (unspecified). In 19 of the 41 
polymicrobial cases, β -haemolytic Streptococcus was part of the infections (group A, n = 11; group B, n = 3; 
group C, n = 2; group G, n = 2; group C + G, n = 1).
Unadjusted*
Adjusted for age, sex, chronic 
disease*
Adjusted for age, sex, chronic 
disease, SAPS II**
OR 95% CI P OR 95% CI P OR 95% CI P
IL-1β
 Low ≤ 2.3 ng/mL 1 1 1
 High > 2.3 ng/mL 3.97 1.49–10.58 0.006 3.86 1.43–10.40 0.008 3.84 1.03–14.31 0.045
IL-6
 Low ≤ 539.2 ng/mL 1 1 1
 High > 539.2 ng/mL 2.52 1.01–6.21 0.047 2.70 1.07–6.83 0.036 1.56 0.48–5.11 0.46
IL-10
 Low ≤ 38.8 μ g/mL 1 1 1
 High > 38.8 μ g/mL 5.17 1.83–14.61 0.002 4.80 1.67–13.78 0.004 2.79 0.74–10.63 0.13
TNF-α
 Low ≤ 15.1 μ g/mL 1 1 1
 High > 15.1 μ g/mL 2.75 1.11–6.81 0.029 2.64 1.04–6.69 0.041 1.55 0.46–5.20 0.48
Table 4.  Univariate and multivariate logistic regression analyses of 30-day mortality in patients with 
necrotising soft tissue infection based on high vs. low concentrations of the cytokines according to median 
values. IL, interleukin; OR, odds ratio; CI, confidence interval; SAPS II, simplified acute physiology score II. *One 
patient was excluded because of loss to follow-up due to emigration. **31 patients were not included in the analysis 
due to missing data of SAPS II (4 of these died within the first 30 days). When the missing variables were replaced 
with the minimal value and maximum value, the median SAPS II was 38 (27–47) and 55 (41–70), respectively.
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to conduct a study with the inclusion of patients with cellulitis or erysipelas to test whether the cytokine profiles 
are able to distinguish between NSTI and these diseases. In addition, future studies should assess the usefulness 
of admission IL-6 and IL-1β determination as prognostic markers used alone or in combination with the LRINEC 
score. This was not possible with the current study as blood samples used in the LRINEC score were obtained at 
a different time point than the samples used for cytokine analyses.
NSTI is classified based on the microbiological aetiology in type 1 (polymicrobial, 70–80%) and type 2 
(monomicrobial, 20–30%)7. In contrast to previous studies and the general belief that NSTI is predominantly pol-
ymicrobial5,25, more patients in our cohort had a monomicrobial infection. We found β -haemolytic Streptococcus, 
predominantly group A, to be the most common causative microorganism, which is in line with two large ret-
rospective studies of 198 and 89 patients with NSTI26,27. We found significantly higher IL-6 and TNF-α levels in 
streptococcal infected patients than in patients infected with other agents. This is consistent with septic shock 
being more prevalent in streptococcal infected patients and levels of these two cytokines being elevated in our 
septic shock cohort. This suggests that plasma levels of IL-6 and TNF-α might be of value clinically to identify 
NSTI cases with systemic inflammation and potentially also as an indication for immunomodulatory treatments 
such as intravenous polyspecific immunoglobulin (IVIG). Although the efficacy of IVIG therapy in sepsis and 
IL-1β IL-6 IL-10 TNF-α LRINEC SAPS II
Sensitivity 0.76 (0.56–0.90) 0.68 (0.48–0.84) 0.80 (0.60–92) 0.68 (0.48–0.84) 0.60 (0.41–0.77) 0.84 (0.65–0.95)
Specificity 0.56 (0.52–0.58) 0.54 (0.50–0.57) 0.56 (0.53–0.59) 0.56 (0.53–0.59) 0.25 (0.21–0.28) 0.59 (0.55–0.61)
PPV 0.24 (0.18–0.29) 0.22 (0.15–0.27) 0.26 (0.19–0.30) 0.23 (0.16–0.28) 0.13 (0.09–0.17) 0.30 (0.23–0.33)
NPV 0.93 (0.86–0.97) 0.90 (0.84–0.95) 0.94 (0.88–0.98) 0.90 (0.84–0.95) 0.77 (0.66–0.87) 0.95 (0.88–0.98)
LR for positive test 1.71 (1.17–2.14) 1.48 (0.97–1.95) 1.83 (1.28–2.23) 1.56 (1.01–2.06) 0.80 (0.52–1.07) 2.05 (1.44–2.44)
LR for negative test 0.43 (0.18–0.85) 0.59 (0.28–1.03) 0.36 (0.13–0.75) 0.57 (0.27–0.99 1.61 (0.81–2.78) 0.27 (0.09–0.64)
Area under ROC curve 0.70 (0.60–0.80) 0.70 (0.58–0.82) 0.70 (0.59–0.80) 0.68 (0.55–0.81) 0.43 (0.30–0.56) 0.80 (0.71–0.90)
Table 5.  Diagnostic accuracy of high baseline biomarker levels in predicting 30-day mortality in patients 
with necrotising soft tissue infection. PPV, positive predictive value; NPV, negative predictive value; LR, 
likelihood ratio; ROC, receiver operating characteristic; IL, interleukin; LRINEC, Laboratory Risk Indicator 
for Necrotizing Fasciitis; SAPS II, Simplified Acute Physiology Score. Data are presented as fractions (95% 
confidence interval). The prevalence of 30-day mortality was 16%. High baseline level defined as being above 
the median value.
Figure 4. Levels of plasma cytokines in 43 non-infected control patients before surgery (baseline) and after 
surgery (2–6 h postoperatively). Comparisons were performed using the Wilcoxon signed-rank test.
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septic shock has been questioned28, certain subgroups of patients with sepsis, such as group A streptococcal 
toxic shock syndrome, have been reported to benefit from the treatment29–31. However, it should be noted that in 
regards to IVIG treatment in NSTI, the clinical evidence is limited to a few case reports and case series32,33. Taken 
together, the IL-6 and TNF-α data seem particularly interesting in light of group A streptococcal NSTI, which is 
often complicated by septic shock and associated with substantial mortality. However, more research is needed 
on these topics.
Our study of NSTI reveals that the infection is characterized by a strong systemic inflammatory response. 
Considering that surgery is a traumatic insult that elicits an inflammatory response, we chose to include a control 
group of non-infected surgical patients. All control samples had significantly lower levels of cytokines compared 
with the NSTI patients. Notably, comparison of pre- and post-surgery samples revealed a significant but limited 
increase in IL-6 and IL-10 levels after surgery, whereas no such difference was seen for IL-1β and TNF-α levels. 
This illustrates how complex and specific the cytokine response profile is in response to different trauma or stim-
uli. In the non-infected surgical control persons, IL-6 increased from 0 to 24 pg/mL after surgery compared with 
the median of 539 pg/mL in the NSTI patients. Thus, the surgery itself is less likely to contribute significantly to 
the increase in IL-6 and IL-10 as seen in the infected patients.
A notable limitation to this study is the measurements of only baseline cytokine values. It would have been 
interesting to investigate the fluctuations in the concentrations over time to elucidate the changes in the biological 
processes. However, the baseline concentrations of the cytokines are the most important values for the clinicians 
as these often guide the course of treatment in the acute phase of the disease. Another limitation is that only four 
different cytokines were analysed. However, we chose well-recognized markers associated with severity of sepsis 
as some of the inflammatory processes probably reflect those in patients with NSTI. We could have included 
several other markers, but this would have increased the risk of chance findings. In addition, it is often difficult to 
correlate the findings of significant biomarkers with the bed-side use. Only few markers have been investigated in 
patients with NSTI and even fewer are used in clinical practice. Interestingly, IL-1β proved to be an independent 
predictor for 30-day mortality. Further support for IL-1β as a potentially useful marker for NSTI was recently pro-
vided in a murine model of streptococcal NSTI, in which IL-1β response network was identified as a key network 
involved in modulating severity of streptococcal NSTI34. Another limitation to this study is the limited time of 
follow-up regarding amputation. We only have data from admission and the following 7 days (defined a priori). 
We might have overlooked relevant amputations performed at later stage. We chose 7 days as follow-up because 
we only wanted to include amputation related specifically to the infection. Importantly, it is our experience from 
the daily clinical settings in all centres that only few of the patients are amputated after the first week of infection. 
Thus, our data provide a realistic picture of the disease course.
We believe that a major future challenge is to identify relevant biomarkers and combine them with clinical 
scores to detect patients with NSTI and improve risk stratification. In this study, we found that IL-1β , IL-6, IL-10 
and TNF-α might be of value in the risk stratification of patients with NSTI with the purpose of enhancing 
prognostication and decision making in these critically ill patients. Furthermore, we found variations in the 
cytokine responses in NSTIs depending on microbial aetiology, suggesting that different pathogenic mechanisms 
contribute to the disease. Future studies should assess the usefulness of admission IL-6 and IL-1β determination 
as prognostic and diagnostic markers in combination with the LRINEC score.
In conclusion, we find that the LRINEC score is not significantly associated with the cytokine response in 
patients with NSTI. In contrast, baseline plasma cytokine levels correlate well with 30-day mortality and dis-
ease severity assessed by SAPS II and SOFA score, the presence of septic shock, infection with β -haemolytic 
Streptococci and subsequent use of RRT and amputation. In the adjusted analyses, IL-1β and IL-10 levels proved 
to have the strongest association with 30-day mortality.
Materials and Methods
Study design. This multicentre, prospective, observational study was approved by the ethics committees and 
Data-Protection agencies in Denmark (the National Committee on Health Research Ethics: 1211709; the regional 
ethics committee: H-2-2014-071), Sweden (the regional ethics committee in Gothenburg; 930-12) and Norway 
(the regional committee for medical and health research ethics, Bergen; 2012/2227). We included patients 
admitted to five Scandinavian hospitals: Righospitalet (Copenhagen, Denmark), Karolinska University Hospital 
(Stockholm, Sweden), Blekingesjukhuset (Karlskrona, Sweden), Sahlgrenska University Hospital (Gothenburg, 
Sweden) and Haukeland University Hospital (Bergen, Norway). Written informed consent was obtained from all 
patients or their next of kin as soon as possible. The study is part of the EU-funded INFECT project and is reg-
istered at ClinicalTrials.gov (NCT01790698). Data from some patients in the Danish cohort have been reported 
elsewhere35,36. The study was carried out in accordance with the relevant guidelines and regulations.
Study patients. Patients with NSTI. We included patients 18 years of age or older with suspected necrosis 
engaging any layer of the soft tissue compartments who had either been admitted to the ICU or undergone sur-
gery for NSTI. We excluded patients in whom surgery revealed no necrosis.
Non-infected surgical control patients. In order to elucidate the cytokine response to surgery and evaluate our 
sampling method, we included patients 18 years of age or older who underwent elective surgery at Rigshospitalet 
(University Hospital of Copenhagen, Denmark). Patients with ongoing infection or inflammatory condi-
tions were excluded (assessed by diagnoses in the medical records and by CRP levels on hospital admission). 
Forty-three control patients, matched for age and sex, were included between September 2014 and March 2015.
Data collection. The following data were obtained from patient medical records by the study trial investiga-
tors or their co-workers: baseline patient characteristics, physiology values, biochemistry, microbiology, chronic 
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diseases, disease severity scores (LRINEC, SAPS II, SOFA), the presence of septic shock (defined as use of vaso-
pressors), use of RRT in the intensive care unit (ICU), and whether the patient had undergone amputation during 
the first seven days of admission. Vital status data were obtained from national registries. All data were entered 
into a centralized clinical database. LRINEC was calculated from 6 variables (C-reactive protein, total white cell 
count, haemoglobin, sodium, creatinine, glucose), a score ≥ 6 indicating a high risk of NSTI, amputation rate and 
mortality12,13,37. SAPS II was calculated from 17 variables, with a higher score indicating more severe disease38. 
SOFA score was calculated based on sub-scores for each of five components: respiratory system, circulatory sys-
tem, liver, kidneys and coagulation, with higher scores indicating more severe organ failure39.
Patients had blood sampled from an arterial line into EDTA tubes upon admission (baseline). All values 
included in the LRINEC score were obtained prior to the first operation. Non-infected control patients had 
venous blood sampled before surgery (baseline) and after surgery (2–6 h postoperatively). The latter sample was 
taken to assess the effect of the surgical trauma on the inflammatory response. All samples were immediately put 
on ice and centrifuged within 40 minutes. The collected plasma was stored at − 80 °C until processing.
Multiplex bead array assays. Analyses were performed in February 2016, thus three months after enrol-
ment of the final patient with NSTI and 11 months after the final control patient. Plasma levels of IL-1β , IL-6, IL-10 
and TNF-α were determined using multiplex bead assays (Bio-Rad Laboratories, Hercules, CA, USA; Bio-Plex 
ProTM assay) according to the manufacturer’s instructions. Analyses were done using the Bio-Plex® MAGPIXTM 
Multiplex Reader (Bio-Rad Laboratories, Hercules, CA, USA). The samples were diluted in 1:4 and 1:10 against 
a standard pool with known concentration and the mean values were calculated after correction for the dilut-
ing steps. According to the manufacturer, the detection range without dilution was: IL-1β (0.2–556 pg/mL), 
IL-6 (5.2–18,618 pg/mL), IL-10 (1.1–11,850 pg/mL) and TNF-α (0.2–2,059 pg/mL) with an intra-assay variation 
of 8% and an inter-assay variation of 10%. Measurements below detection limit were set to 0. One patient had 
an IL-6 level above detection range, when taking the dilution factor into account, and was set to 180,000 pg/mL.
Outcome measures. According to our published protocol40, the primary analysis was baseline IL-6 level in 
patients with NSTI and a LRINEC score < 6 vs. ≥6. IL-6 was chosen because it is an important mediator of the 
acute inflammatory response and a recognized biomarker in sepsis8. A LRINEC cut-off ≥ 6 was chosen because 
it has proven to have the highest predictive values and because of an expected higher amputation and mortality 
rate, making it clinically relevant12,13. Secondary analyses included the association between baseline IL-1β , IL-6, 
IL-10 and TNF-α level and SAPS II, SOFA score, septic shock on Day 1 in the ICU, β -haemolytic streptococcal 
infection, use of RRT in the ICU, amputation within the first seven days of admission and 30-day mortality. There 
was no standardized protocol for use of RRT or amputation.
Statistical analysis. Categorical data are presented as absolute numbers (%) and continuous data as medians 
(IQR). For the primary analysis, the unpaired Student t-test was applied and quantified by a 95% confidence inter-
val (CI). Comparisons were performed using unadjusted χ 2 tests for binary outcome measures, Mann-Whitney 
U tests for unpaired analyses and Wilcoxon-rank tests were used for paired analyses. We assessed correlations 
by Spearman’s rank correlation tests. We used logistic regression analyses with odds ratios (OR) and 95% CI to 
assess the correlation between baseline biomarker levels and 30-day mortality and adjusted for differences in 
baseline variables (sex, age, SAPS II and chronic disease [diabetes, liver cirrhosis, chronic kidney disease, cardio-
vascular disease, chronic obstructive pulmonary disease, peripheral vascular disease, immune deficiency, malig-
nancy, rheumatoid disease]). Receiver operating characteristic (ROC) curves were analysed for 30-day mortality. 
Patients with missing SAPS II data were excluded from the part of the multiple logistic regression analysis where 
adjustment for SAPS II was performed.
Analyses were performed with Statistical Package for the Social Sciences 22.0 software (SPSS Inc., Chicago, IL, 
USA) and GraphPad Prism 6.0 software (GraphPad Inc., La Jolla, CA, USA). P-values < 0.05 were considered to 
indicate statistical significance.
Sample size. We considered a difference in IL-6 level of 1000 pg/mL as clinically relevant because previous 
studies have found similar differences between sepsis patients according to shock19,20. In a pilot study of seven 
patients with NSTI, we found a standard deviation in IL-6 on admission of 2000 pg/mL. Based on this, we decided 
to include 159 patients as this would allow the detection of a difference of 1000 pg/mL with a statistical power of 
at least 85% at the 5% significance level. The 159 patients were selected randomly out of the total cohort of 202 
NSTI patients with a LRINEC score using a computer-generated allocation table.
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